Management of Iron Overload in Liver Cirrhosis with Hemosiderosis
Patients with liver cirrhosis and hemosiderosis should undergo comprehensive evaluation to determine the cause and severity of iron overload, followed by therapeutic phlebotomy when iron overload is confirmed and the patient can tolerate it, targeting ferritin levels of 50-100 μg/L.
Initial Evaluation
Determine the Cause of Iron Overload
- Distinguish between primary (hereditary hemochromatosis) and secondary iron overload, as this fundamentally changes management 1, 2.
- Order HFE gene testing (C282Y and H63D mutations) to identify hereditary hemochromatosis, though cirrhosis itself commonly causes secondary iron accumulation 3, 4.
- Recognize that iron overload is common in cirrhosis (32-44% prevalence) and often represents acquired hemosiderosis rather than hereditary disease, even when hepatic iron index exceeds 1.9 4.
- Secondary iron overload in cirrhosis is more common in non-biliary cirrhosis (22-67% of cases) compared to biliary cirrhosis (7-20%) 4.
Quantify Iron Burden
- Use MRI to quantify hepatic iron concentration as the primary non-invasive method, as it is now considered standard of care 3, 5, 6.
- MRI should be performed in patients with unclear hyperferritinemia, biochemical iron overload, or positive liver iron staining to quantify hepatic iron and assess extrahepatic organ involvement 3.
- Measure serum ferritin and transferrin saturation as initial screening tests, though these must be interpreted cautiously in cirrhosis where ferritin may be elevated due to inflammation 3, 2.
- Liver biopsy is NOT recommended for diagnosing hepatic iron overload but may be considered if ferritin >1,000 μg/L or liver enzymes are elevated to assess fibrosis stage 3.
Assess Fibrosis and Cirrhosis Status
- All patients should undergo non-invasive assessment of liver fibrosis at diagnosis using transient elastography or FIB-4 score 3.
- Transient elastography with liver stiffness <6.4 kPa can rule out advanced fibrosis in hemochromatosis patients 3.
- In patients with ferritin <1,000 μg/L, normal transaminases, and no hepatomegaly, the risk of advanced fibrosis is very low 3.
Screen for Extrahepatic Complications
- Evaluate for cardiac involvement with ECG and echocardiography in patients with severe iron overload 3.
- Cardiac MRI should be performed in patients with severe hemochromatosis and signs/symptoms of heart disease for myocardial iron quantification 3.
- Assess for endocrine complications including diabetes, hypogonadism, and thyroid dysfunction 3.
- Evaluate for arthropathy, particularly involving metacarpophalangeal joints, which is common in hemochromatosis 3.
Treatment Strategy
Phlebotomy Therapy
Therapeutic phlebotomy is the primary treatment for iron overload in cirrhosis when patients can tolerate it 7.
Phlebotomy Protocol:
- Perform weekly phlebotomy (500 mL blood removal) as tolerated during the initial depletion phase 7.
- Check hemoglobin/hematocrit before each phlebotomy and allow no more than 20% decline from baseline 7.
- Monitor ferritin every 10-12 phlebotomies to track progress 7.
- Target ferritin level of 50-100 μg/L as the therapeutic endpoint 7.
- Continue maintenance phlebotomy at intervals to maintain ferritin between 50-100 μg/L after initial depletion 7.
Important Caveats:
- Advanced cirrhosis is NOT reversed by iron removal, though phlebotomy may slow disease progression 7.
- In patients with decompensated cirrhosis who cannot tolerate phlebotomy, consider liver transplantation evaluation 7.
- Phlebotomy can have beneficial effects on liver histology in compensated cirrhosis with iron overload 2.
Alternative Therapies When Phlebotomy is Contraindicated
- Iron chelation therapy with deferoxamine (20-40 mg/kg/day) or oral deferasirox should be considered in patients who cannot tolerate phlebotomy, particularly those with anemia or dyserythropoiesis 7.
- Chelation therapy is less efficient than phlebotomy, removing only 10-20 mg iron/day compared to 250 mg/week with phlebotomy 7.
Dietary and Lifestyle Modifications
- Avoid vitamin C supplements, as they accelerate iron mobilization and can increase oxidative stress 7.
- Avoid iron supplements 7.
- Avoid raw shellfish due to risk of Vibrio vulnificus infection in iron-overloaded patients 7.
- Dietary iron restriction is unnecessary, as it provides minimal benefit (only 2-4 mg/day reduction) 7.
Hepatocellular Carcinoma Surveillance
Patients with cirrhosis and hemosiderosis require intensive HCC surveillance regardless of iron depletion status.
- Perform HCC screening with abdominal ultrasound every 6 months in all patients with cirrhosis 3.
- Continue HCC surveillance indefinitely, even after successful iron depletion, as cirrhosis itself confers ongoing cancer risk 3.
- Consider HCC screening in patients with advanced fibrosis (F3) even without cirrhosis 3.
- Use CT or MRI when ultrasound is technically suboptimal 3.
Special Considerations
Distinguishing Primary from Secondary Iron Overload
- Cirrhosis itself causes iron accumulation rapidly once established, making hepatic iron index >1.9 unreliable for diagnosing hereditary hemochromatosis in the presence of cirrhosis 4.
- Only 5 of 447 cirrhotic livers with iron overload in one study had true homozygous hemochromatosis as the cause of cirrhosis 4.
- Genotype should not solely guide treatment decisions; phenotypic presentation and additional risk factors are more important 3.
Monitoring During Treatment
- Iron reaccumulation is common and requires ongoing monitoring with maintenance phlebotomy 7.
- Excess iron increases oxidative stress and accelerates liver disease progression, making treatment important even in established cirrhosis 2.
Transplantation Considerations
- Adequate iron removal before liver transplantation is critical, as inadequate depletion historically led to increased perioperative mortality from cardiac and infectious complications 7.
- Current survival after transplantation is comparable to other etiologies when iron is adequately depleted pre-transplant 7.